Skip to content
Malta's world news feed Local perspective with global outlook
CDE.NEWS The Dispatch
Norway

Three people in Norway treated for “unusual symptoms” after AstraZeneca COVID-19 shots

Health workers fill a syringe with a Covid-19 vaccine dose in Drammen, Norway, 21 January 2021. The vaccination of residents in Drammen who are over 85 years old and who do not live in a nursing home started. In Drammenshallen, 150 people and about 40 health personnel received their first Covid-19 vaccine helped by around 35 employees from various companies in the municipality. EPA-EFE/Ole Berg-Rusten NORWAY OUT

OSLO, March 13 (Reuters) – Three health workers in Norway who had recently received the AstraZeneca COVID-19 vaccine are being treated in hospital for bleeding, blood clots and a low count of blood platelets, Norwegian health authorities said on Saturday.

Norway halted the rollout of the AstraZeneca vaccine on Thursday, following a similar move by Denmark. Iceland later followed suit.

“We do not know if the cases are linked to the vaccine,” Sigurd Hortemo, a senior doctor at the Norwegian Medicines Agency told a news conference held jointly with the Norwegian Institute of Public Health.

All three individuals were under the age of 50.

The European medicine regulator, the European Medicines Agency (EMA,) would investigate the three incidents, Hortemo said.

“They have very unusual symptoms: bleeding, blood clots and a low count of blood platelets,” Steinar Madsen, Medical Director at the Norwegian Medicines Agency told broadcaster NRK.

“They are quite sick…We take this very seriously,” he said, adding that authorities had received notification of the cases on Saturday.

AstraZeneca said an analysis of its safety data covering reported cases from over 17 million vaccine doses given had shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia – having low levels of platelets.

“In fact, the reported numbers of these types of events for COVID-19 Vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population,” a company spokeswoman said.

Such trends or patterns were also not observed during clinical trials for the vaccine, she added.

Before Denmark and Norway stopped their rollout of the AstraZeneca vaccine, Austria stopped using a batch of the shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.

The EMA said on Thursday the vaccine’s benefits outweighed its risks and that it could continue to be administered.

Europe is struggling to speed up a vaccine rollout after delivery delays from Pfizer and AstraZeneca, even though new cases have spiked in some countries.

(Reporting by Gwladys Fouche, editing by Terje Solsvik)

Filed under CoronavirusNorway

More from Norway

More →